Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - Bilateral multifocal (BMF) papillary type I renal cell carcinoma (RCC) has traditionally been associated with hereditary papillary renal cell carcinoma (HPRC) with mutations of the met proto-oncogene. However, non-familial forms of this cancer also exist, yet are poorly characterized. Okoro et al. from the National Cancer Institute (NCI) describe their institutional experience with this rare clinical entity.

auaThe authors retrospectively evaluated 61 patients who had been treated at the NCI for BMF papillary type I RCC, which was negative for the met mutation, between 1996 and 2013. Over this time period, patients were managed with percutaneous tumor biopsy and partial nephrectomy when the tumor reached 3 cm in size. The NCI group found that patients with this type of RCC were disproportionately men (93.4%) and African American (34.4%). At presentation, this patient cohort presented with an average serum creatinine of 1.48 mg/dl and eGFR of 62.5 mL/min, findings of stage II CKD. At average follow-up of 32.9 months, no patients presented with metastatic disease. However, African American patients experienced an especially marked decrease in renal function.

The authors concluded that management with active surveillance and nephron sparing surgery when tumors are ≥ 3 cm is both reno-protective and oncologically sound in this patient population. Further research is necessary to determine the metabolic and genetic basis for this form of BMF papillary type I RCC, as well as to determine which specific populations are at the greatest risk.

Presented by Chionyerem Okoro, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

National Cancer Institute (NCI), Bethesda, MD USA

Written by Dima Raskolnikov, National Cancer Institute (NCI)

 

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe